PubRank

J F San Miguel

Author PubWeight™ 175.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999 4.09
2 Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007 1.99
3 High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999 1.84
4 Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999 1.83
5 Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2012 1.74
6 Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2006 1.73
7 Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010 1.66
8 Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998 1.55
9 Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999 1.55
10 Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003 1.52
11 Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. Am J Hematol 1993 1.48
12 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res 1983 1.48
13 Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica 1998 1.48
14 SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia 2012 1.45
15 Minimal residual disease in leukaemia patients. Lancet Oncol 2001 1.43
16 Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant 1999 1.41
17 Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplant 2004 1.41
18 Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989 1.31
19 MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia 2013 1.30
20 Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009 1.29
21 Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006 1.29
22 Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005 1.27
23 Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005 1.26
24 BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000 1.24
25 Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000 1.23
26 Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001 1.22
27 Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006 1.20
28 BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997 1.19
29 Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998 1.17
30 Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003 1.14
31 Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain. Haematologica 2001 1.12
32 Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol 2001 1.11
33 Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002 1.11
34 Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol 1984 1.10
35 High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003 1.08
36 The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2012 1.07
37 Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 2005 1.05
38 Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells. Clin Exp Immunol 1999 1.05
39 Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol 2001 1.04
40 Cell surface markers in multiple myeloma. Mayo Clin Proc 1994 1.04
41 Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods. Cytometry 2001 1.02
42 BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001 1.02
43 Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996 1.02
44 The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies. Semin Oncol 1984 1.00
45 Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998 0.99
46 Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 1996 0.99
47 Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005 0.98
48 Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. Br J Haematol 1986 0.97
49 Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. I. Ultrastructural morphology and cytochemistry. Br J Haematol 1985 0.97
50 Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005 0.96
51 Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998 0.96
52 Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999 0.94
53 Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996 0.94
54 Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007 0.93
55 Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002 0.93
56 Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 1997 0.92
57 Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. Transfusion 2001 0.92
58 Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003 0.91
59 Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 1992 0.91
60 Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001 0.91
61 Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 1996 0.91
62 Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004 0.90
63 Iron metabolism and fungal infections in patients with haematological malignancies. J Clin Pathol 1995 0.90
64 Immunophenotypic characterisation of acute leukaemia after polycythemia vera. J Clin Pathol 1993 0.90
65 Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001 0.90
66 A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 2013 0.90
67 De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 2000 0.89
68 Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia 2007 0.89
69 Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004 0.89
70 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007 0.88
71 Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant 2012 0.87
72 The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004 0.87
73 Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol (Paris) 1999 0.87
74 Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. Am J Pathol 1996 0.86
75 Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. Haematologica 1999 0.86
76 Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. Haematologica 1999 0.86
77 Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol 2008 0.86
78 Heterogeneity of T cell lymphoblastic leukaemias. J Clin Pathol 1991 0.86
79 p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001 0.86
80 Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. Leukemia 2003 0.86
81 Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996 0.85
82 Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993 0.85
83 Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol 2001 0.85
84 Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. Cytotherapy 2007 0.85
85 Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997 0.85
86 Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples. Anal Cell Pathol 1998 0.85
87 Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia 1992 0.85
88 Translocation (15;17)(q22;q21) in a patient with Klinefelter syndrome. Cancer Genet Cytogenet 1996 0.85
89 Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. Leukemia 2003 0.85
90 Chronic myelomonocytic leukemia--clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur J Haematol 1989 0.84
91 Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica 2001 0.84
92 Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution. Ann Hematol 1993 0.84
93 A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994 0.84
94 Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Cytometry 1998 0.84
95 Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. II. Studies with monoclonal antibodies and terminal transferase. Br J Haematol 1985 0.83
96 Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside. Leukemia 1992 0.83
97 Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. Transfus Med 2012 0.83
98 Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996 0.83
99 Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transpl Infect Dis 2001 0.83
100 Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997 0.82
101 Pathologic rupture of the spleen during induction with ATRA in a patient with acute promyelocytic leukemia. Med Oncol 2000 0.82
102 Rhabdomyolysis associated with septicemia after autologous bone marrow transplantation. Bone Marrow Transplant 1997 0.82
103 Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias. Clin Lab Haematol 1985 0.82
104 Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant 2006 0.82
105 Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. Leukemia 2001 0.82
106 Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994 0.82
107 Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. Eur J Haematol 1996 0.82
108 CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymphoma 2005 0.82
109 Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001 0.82
110 Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998 0.81
111 Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain). Tissue Antigens 2011 0.81
112 Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment. Leuk Res 2012 0.81
113 The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999 0.81
114 Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004 0.81
115 Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993 0.81
116 Immune thrombocytopenic purpura secondary to endometriosis. Haematologica 1998 0.81
117 Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001 0.81
118 Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann Hematol 1997 0.80
119 Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells. Haematologica 2000 0.80
120 Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001 0.80
121 Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol 1998 0.80
122 The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br J Haematol 1999 0.80
123 Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. Br J Haematol 1995 0.80
124 Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol 1992 0.80
125 Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990 0.80
126 Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. Haematologica 1998 0.80
127 Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009 0.80
128 Coexpression of T- and B-markers in a lymphoproliferative disorder. Scand J Haematol 1986 0.80
129 Molecular biology of myeloma. Clin Transl Oncol 2007 0.80
130 Two cases of myeloid disorders and a t(8;12) (q12;p13). Haematologica 2000 0.79
131 [Phenotypic changes in refractory and relapse acute lymphoblastic leukemias]. Sangre (Barc) 1991 0.79
132 Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 1999 0.79
133 Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. Cytometry 1995 0.79
134 Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. Br J Haematol 1995 0.79
135 Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br J Cancer 1993 0.79
136 Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain. Br J Haematol 1999 0.79
137 Plasmablastic multiple myeloma: an immunologically different subtype. Br J Haematol 1987 0.79
138 Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Br J Haematol 1995 0.79
139 Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. Br J Haematol 1991 0.79
140 Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia. Haematologia (Budap) 1990 0.79
141 T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. Am J Hematol 1985 0.78
142 In vitro growth in acute myeloblastic leukaemia: relationship with other clinico-biological characteristics of the disease. Br J Haematol 1998 0.78
143 T cells subpopulations in untreated and treated patients with haemophilia A and B. Blut 1983 0.78
144 The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000 0.78
145 The effect of vitamin D3 metabolites on normal and leukemic bone marrow cells in vitro. Int J Cell Cloning 1984 0.78
146 Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes. Leukemia 2004 0.78
147 In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression. Transfus Apher Sci 2007 0.78
148 Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 0.78
149 Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998 0.78
150 Long lasting immunological effects of ethanol after withdrawal. Cytometry 1996 0.78
151 Do myelomatous plasma cells really express surface immunoglobulins? Haematologica 1997 0.78
152 Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997 0.78
153 The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens 2008 0.78
154 Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. Haematologica 1998 0.78
155 Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia 1998 0.77
156 The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica 1998 0.77
157 Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry 1998 0.77
158 Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia. Recent Results Cancer Res 1993 0.77
159 Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 2006 0.77
160 Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype. J Clin Pathol 1995 0.77
161 Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica 2001 0.77
162 IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. Br J Haematol 1998 0.77
163 Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. Br J Haematol 1986 0.77
164 [Prognostic factors and stages in multiple myeloma]. Sangre (Barc) 1984 0.77
165 Cytokine therapy in multiple myeloma. Br J Haematol 1996 0.77
166 Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. J Biol Regul Homeost Agents 2005 0.76
167 TdT activity in acute myeloid leukemias defined by monoclonal antibodies. Am J Hematol 1986 0.76
168 [Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation]. Med Clin (Barc) 1998 0.76
169 Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation. Transpl Infect Dis 2000 0.76
170 [Chronic B-cell lymphatic leukemia: autoimmune hemolytic anemias versus anemias caused by marrow failure]. Sangre (Barc) 1988 0.76
171 Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Bone Marrow Transplant 1999 0.76
172 Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias. J Biol Regul Homeost Agents 2004 0.76
173 Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. Bone Marrow Transplant 2000 0.76
174 Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol 1999 0.76
175 Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 0.76
176 Flow cytometry in the diagnosis of cancer. Scand J Clin Lab Invest Suppl 1995 0.76
177 Randomized study of filgrastim versus molgramostim after peripheral stem cell transplant in breast cancer. Haematologica 1998 0.75
178 Responsiveness of AML cells to recombinant hematopoietic growth factors: relationship with morphological and immunological characteristics of blast cells. Leuk Res 1996 0.75
179 Method for the simultaneous labelling of terminal deoxynucleotidyl transferase (TdT) and membrane antigens. J Clin Pathol 1984 0.75
180 Biphenotypic leukemia in treated Hodgkin's disease. J Clin Pathol 1984 0.75
181 Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia. Leukemia 1999 0.75
182 Bone marrow necrosis and treatment with interferon. J Clin Pathol 1986 0.75
183 Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia. J Clin Pathol 1996 0.75
184 Clinical and phenotypical characteristics of pre-T-cell leukemia. Blood 1990 0.75
185 Chronic prolymphocytoid leukaemia with an unusual immature immunophenotype. J Clin Pathol 1994 0.75
186 Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995 0.75
187 Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection. Br J Haematol 1996 0.75
188 [Megakaryoblastic leukemias]. Sangre (Barc) 1989 0.75
189 [The megakaryoblastic component of mixed blast crises]. Sangre (Barc) 1985 0.75
190 [Myelodysplastic syndromes: characterization of a series of 56 patients classified according to FAB criteria]. Sangre (Barc) 1987 0.75
191 [Control of oral anticoagulant treatment using an automated method]. Sangre (Barc) 1994 0.75
192 Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders. Ann Hematol 1997 0.75
193 [Morphologic/immunologic phenotype discrepancy in B-cell acute lymphoblastic leukemia]. Sangre (Barc) 1986 0.75
194 An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. Cytometry 1999 0.75
195 [The importance of terminal deoxyribonucleotidyl transferase in myeloblastic leukemias. Apropos of 2 cases]. Sangre (Barc) 1983 0.75
196 Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. Eur J Cancer Clin Oncol 1987 0.75
197 [Waldenström's disease with osteolytic lesions, renal failure and amyloidosis]. Med Clin (Barc) 2000 0.75
198 In vitro autonomous proliferation in ANLL: clinical and biological significance. Leuk Res 1995 0.75
199 Immunological markers of peripheral blood and lymph node lymphocytes in Hodgkin's disease. Neoplasma 1985 0.75
200 Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. Cytometry 1999 0.75
201 Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995 0.75
202 TCR-gamma gene rearrangement with interstitial deletion within the TRGV2 gene segment is not detected in normal T-lymphocytes. Leukemia 1998 0.75
203 [Membrane markers in chronic lymphoproliferative diseases]. Med Clin (Barc) 1983 0.75
204 [Analysis of parameters discriminating between stage I myelomas and essential monoclonal gammapathies]. Med Clin (Barc) 1986 0.75
205 Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. Clin Immunol Immunopathol 1985 0.75
206 Myelodysplastic syndrome evolving to a mixed myeloid-lymphoid leukaemia. Hematol Oncol 1986 0.75
207 [Syndrome of abnormal chromatin clumping in leucocytes with a high fraction of bone marrow cells in S-phase and in vitro autonomous growth]. Med Clin (Barc) 1997 0.75
208 [Comparative study of the FAB classification and an immunologic classification model for the acute myeloid leukemias]. Sangre (Barc) 1988 0.75
209 [Non-Hodgkin's lymphomas. II. Prognostic factors]. Sangre (Barc) 1988 0.75
210 B-cell chronic lymphocytic leukaemia: prognostic value of the immunophenotype and the clinico-haematological features. Am J Hematol 1989 0.75
211 [Study of leukemic colony-forming units (CFU-L) in non-lymphoblastic malignant hemopathies]. Sangre (Barc) 1989 0.75
212 [Long-term culture: evidence of the capacity of stroma to sustain hematopoiesis of a second inoculum]. Sangre (Barc) 1996 0.75
213 The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. Eur J Haematol 2009 0.75
214 Changes in surface antigens of HL-60 cells during differentiation in vitro. Blut 1984 0.75
215 Skin involvement in non-secretory myeloma. Am J Med 1988 0.75
216 [Monoclonal gammopathies: classical parameters and beta 2 microglobulins in the differential diagnosis]. Sangre (Barc) 1984 0.75
217 T-cell subsets and myeloma cell mass. Am J Hematol 1987 0.75
218 [Comparative genomic hybridization. Methodologic features]. Sangre (Barc) 1999 0.75
219 [Spinal cord compression as the presenting form of non-Hodgkin's lymphoma]. Sangre (Barc) 1995 0.75
220 Debate round-table: comments concerning chimerism studies. Leukemia 2001 0.75
221 Histiocytic cytophagic panniculitis: a rare late complication of allogeneic bone marrow transplantation. Bone Marrow Transplant 1994 0.75
222 Surface phenotype and clinical stages in B-cell chronic lymphocytic leukaemia. Haematologica 1987 0.75
223 The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. Blut 1986 0.75
224 [Immunologic phenotype of chronic T lymphatic leukemia]. Med Clin (Barc) 1984 0.75
225 Immunological phenotype of the microgranular variant of acute promyelocytic leukaemia. Haematologia (Budap) 1987 0.75
226 [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes]. Med Clin (Barc) 1991 0.75
227 Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. Br J Haematol 2000 0.75
228 Osteolytic lesion as the presenting feature of chronic granulocytic leukaemia. Clin Lab Haematol 1985 0.75
229 Expression of immunologic markers in megakaryoblasts. Blood 1987 0.75
230 Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. Clin Biochem 2000 0.75
231 [Clinico-pathological features and clinical stages in chronic lymphatic leukemia. Multivariate analysis]. Sangre (Barc) 1986 0.75
232 [Immunologic characterization of hairy-cell leukemia or tricholeukemia]. Sangre (Barc) 1984 0.75
233 In vitro growth in acute myeloblastic leukemia: clinico-biological correlations. Leuk Lymphoma 1999 0.75
234 [Acquired immunodeficiency syndrome and the treatment of hemophilia]. Med Clin (Barc) 1983 0.75
235 Neurological complications after autologous stem cell transplantation. Eur Neurol 1999 0.75
236 Cytochemistry in the differential diagnosis of monoclonal gammopathies. Br J Haematol 1985 0.75
237 [Results of a series of 104 consecutive bilateral bone marrow biopsy specimens in lymphoproliferative disorders]. Sangre (Barc) 1995 0.75
238 Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. Ann Hematol 1997 0.75
239 Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. Clin Immunol Immunopathol 1988 0.75
240 Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by fish. Haematologica 1998 0.75
241 Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematol Oncol 2006 0.75
242 [Non-Hodgkin's lymphomas. I. Clinico-biological features in a series of 98 patients]. Sangre (Barc) 1988 0.75
243 Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ara-C. Haematologica 1998 0.75
244 Multiparametric cell-cycle analysis of peripheral blood-activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd. Cytometry 1996 0.75
245 The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia. Hematol Oncol 1991 0.75
246 Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk Lymphoma 2004 0.75
247 [Effect of a leukocyte medium conditioned with PHA on the proliferation and differentiation of leukemic cells]. Sangre (Barc) 1988 0.75
248 [Molecular biology in malignant blood diseases. Methodological aspects: Southern blotting techniques and the polymerase chain reaction]. Sangre (Barc) 1996 0.75
249 Discrepancies between morphologic, cytochemical, and immunologic characteristics in acute myeloblastic leukemia. Am J Clin Pathol 1987 0.75
250 [Immunologic and enzymatic markers of acute infantile lymphoblastic leukemias]. An Esp Pediatr 1984 0.75
251 In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis. Leuk Res 1997 0.75
252 Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000 0.75
253 [Molecular biology in malignant blood diseases. Clinical applications. Study of immunoglobulin and T-cell receptor genes and molecular analysis of the translocations]. Sangre (Barc) 1996 0.75
254 Clonality analysis for antigen receptor genes: preliminary results from the Biomed-2 concerted action PL 96-3936. Hum Pathol 2003 0.75
255 [High cardiac output in myeloma patients. Its prevalence and clinical characteristics. The Castile-León Cooperative Group for the Study of Monoclonal Gammapathies]. Med Clin (Barc) 1997 0.75
256 Cell lineage switches in blast crisis of a Ph1 positive chronic granulocytic leukemia. Haematologica 1987 0.75
257 [Cytochemistry of tricholeukemia]. Sangre (Barc) 1983 0.75
258 [Lymphocyte populations in hemophilia A and B. Relation to acquired immunodeficiency syndrome and therapeutic implications]. Sangre (Barc) 1983 0.75
259 The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. Ann Hematol 1994 0.75
260 Hybrid acute leukaemia. Br J Haematol 1987 0.75
261 Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematol Cell Ther 1997 0.75
262 [Immunologic phenotypes of acute lymphoblastic leukemias and their clinico-biological correlations]. Sangre (Barc) 1984 0.75
263 Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. Thromb Res 2006 0.75
264 Immunoblastic lymphoma and associated non-lymphoid malignancies following two cases of Waldenström's macroglobulinemia. A review of the literature. Eur J Haematol 1993 0.75
265 Helper/suppressor T-cell subpopulations in benign paraproteinaemia. Br J Haematol 1983 0.75
266 [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value]. Sangre (Barc) 1989 0.75
267 Heterogeneity of chronic T-cell lymphocytosis: immunological and clinical aspects. Haematologia (Budap) 1987 0.75
268 Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. Bone Marrow Transplant 2004 0.75
269 Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol 2002 0.75
270 [Phenotypic characterization of normal myeloid differentiation]. Sangre (Barc) 1994 0.75
271 [Invasive aspergillosis in patients with malignant hemopathies. Usefulness of direct and serologic diagnosis]. Sangre (Barc) 1993 0.75
272 [Clonogenic cells of acute leukemia secondary to myeloproliferative and myelodysplastic syndromes]. Sangre (Barc) 1994 0.75
273 [The clonogenic cell in acute myeloblastic leukemia]. Sangre (Barc) 1990 0.75
274 Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. Leukemia 2001 0.75
275 [Autologous transplant with BEAM protocol in lymphoma]. Sangre (Barc) 1997 0.75
276 DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers. Cytometry 1995 0.75